Nexalin Technology, Inc. (NXL) Stock Price & Analysis
Nexalin Technology, Inc. (NXL) rose 2.82% to USD 0.48 as of July 25, 2026 at 17:45 UTC, according to Nexqual real-time market data.
NXL last closed at USD 0.47; the session ranged USD 0.48–0.5 on volume of 122,603 shares. Market capitalization is $10.59M, with a 52-week range of USD 0.31–2 (NCM). Source: Nexqual, July 25, 2026 at 17:45 UTC.
Key Statistics (as of July 25, 2026 at 17:45 UTC)
| Price | USD 0.48 |
|---|---|
| Change | ▲ 2.82% (up) |
| Previous Close | USD 0.47 |
| Open | USD 0.48 |
| Day Range | USD 0.48 – 0.5 |
| 52-Week Range | USD 0.31 – 2 |
| Volume | 122,603 shares |
| Market Cap | $10.59M |
| Exchange | NCM |
Technical Analysis (NXL)
Nexqual's technical model rates NXL "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 17:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.05 (neutral) |
| vs SMA50 | Above (USD 0.43) |
| MACD | 0.02 (positive) |
Analyst Ratings (NXL)
Wall Street analysts rate NXL "None" based on 1 analysts, with a mean price target of USD 2 (range USD 2–2), per Nexqual as of July 25, 2026 at 17:45 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 2 |
| High Target | USD 2 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (NXL)
| EPS Estimate | USD -0.1 |
|---|---|
| Revenue Estimate | $90,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.11 vs est -0.1 ▼ miss |
| 2025-12-31 | USD -0.13 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.13 vs est -0.12 ▼ miss |
| 2025-06-30 | USD -0.1 vs est -0.14 ▲ beat |
Source: Nexqual, July 25, 2026 at 17:45 UTC.
Financials & Fundamentals (NXL)
| Total Revenue | $275,582 |
|---|---|
| Revenue Growth (YoY) | -63.60% |
| Gross Margin | +81.99% |
| Operating Margin | -14179.95% |
| Profit Margin | +0.00% |
| ROE | -319.69% |
| Current Ratio | 4.07 |
| Total Cash | $2.71M |
| Total Debt | $0 |
| Free Cash Flow | $-2.25M |
Source: Nexqual, July 25, 2026 at 17:45 UTC.
Financial Health Score (NXL)
Nexqual rates Nexalin Technology, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 17:45 UTC.
| Growth | Strong — Revenue +79% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -320%, ROA -161.1% |
Ownership (NXL)
| Insider Ownership | +10.50% |
|---|---|
| Institutional Ownership | +4.89% |
| Shares Outstanding | 22.01M |
| Float | 17.98M |
| Short % of Float | +3.08% |
Source: Nexqual, July 25, 2026 at 17:45 UTC.
Leadership (NXL)
Nexalin Technology, Inc. is led by Mark White (age 63), President, CEO & Director, per Nexqual as of July 25, 2026 at 17:45 UTC.
| President, CEO & Director | Mark White (age 63) |
|---|---|
| Chief Medical Officer, Member of Scientific Advisory Board & Director | David Owens (age 63) |
| Co-Founder and Director of Engineering & Development | John Patrick Claude |
| Chief Financial Officer | Justin Van Fleet (age 44) |
Major Backers & Investors (NXL)
Notable institutional backers of Nexalin Technology, Inc. include Peak6 LLC, Fidelity, HRT Financial LP, according to Nexqual as of July 25, 2026 at 17:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Peak6 LLC | 1.75% |
| Fidelity | 1.02% |
| HRT Financial LP | 0.11% |
| Kovack Advisors, Inc. | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.37% |
| Geode Capital | 1.12% |
| State Street | 0.15% |
| Northern Trust | 0.11% |
Source: Nexqual, July 25, 2026 at 17:45 UTC.
From Nexalin Technology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- We have a proprietary and protected design that stabilizes currents, electromagnetic fields, and various frequencies — referred to collectively as a waveform — particularly our proprietary, 15 milliamp patented waveform.
- We developed an easy-to-administer medical device — referred to as "Generation 1" or "Gen-1" — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy.
- This revenue consists of monthly license fees and payment for the sale of electrodes to clinical providers of our technology.
Partnerships
- The Nexalin regulatory team and the FDA came to a consensus on the Insomnia Clinical research protocols for insomnia assessment scales and timeline end points and patient population size.   In February 2026, the Company entered into a short-term start-up agreement with Lindus Health Limited to support limited clinical trial preparation activities while a broader services agreement is under negotiation.
- The Nexalin virtual clinic will be provided in a proprietary virtual platform currently in the design stage.   In February 2026, the Company entered into a non-binding memorandum of understanding with GreenLight Venture LLC to evaluate a potential strategic collaboration.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRE | Cre8 Enterprise Limited | USD 2.54 | ▼ 6.27% |
| NHP | National Healthcare Properties, | USD 16 | ▲ 0.5% |
| BIVI | BioVie Inc. | USD 1.37 | ▲ 2.24% |
| CLDI | Calidi Biotherapeutics, Inc. | USD 0.1 | ▼ 5.66% |
| AIMD | Ainos, Inc. | USD 1.4 | ▼ 9.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 17:45 UTC. This page is informational and not investment advice.